Literature DB >> 35427499

Modular design of synthetic receptors for programmed gene regulation in cell therapies.

Iowis Zhu1, Raymond Liu1, Julie M Garcia1, Axel Hyrenius-Wittsten2, Dan I Piraner1, Josef Alavi1, Divya V Israni3, Bin Liu4, Ahmad S Khalil5, Kole T Roybal6.   

Abstract

Synthetic biology has established powerful tools to precisely control cell function. Engineering these systems to meet clinical requirements has enormous medical implications. Here, we adopted a clinically driven design process to build receptors for the autonomous control of therapeutic cells. We examined the function of key domains involved in regulated intramembrane proteolysis and showed that systematic modular engineering can generate a class of receptors that we call synthetic intramembrane proteolysis receptors (SNIPRs) that have tunable sensing and transcriptional response abilities. We demonstrate the therapeutic potential of the receptor platform by engineering human primary T cells for multi-antigen recognition and production of dosed, bioactive payloads relevant to the treatment of disease. Our design framework enables the development of fully humanized and customizable transcriptional receptors for the programming of therapeutic cells suitable for clinical translation.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR-T cells; cancer immunotherapy; cell therapy; synNotch; synthetic biology

Mesh:

Substances:

Year:  2022        PMID: 35427499      PMCID: PMC9108009          DOI: 10.1016/j.cell.2022.03.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  49 in total

1.  Crystal structure of the human Pax6 paired domain-DNA complex reveals specific roles for the linker region and carboxy-terminal subdomain in DNA binding.

Authors:  H E Xu; M A Rould; W Xu; J A Epstein; R L Maas; C O Pabo
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

2.  Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization.

Authors:  Marc Vooijs; Eric H Schroeter; Yonghua Pan; Mary Blandford; Raphael Kopan
Journal:  J Biol Chem       Date:  2004-09-23       Impact factor: 5.157

3.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

4.  Determination of Lentiviral Infectious Titer by a Novel Droplet Digital PCR Method.

Authors:  Yu Wang; Svetlana Bergelson; Marina Feschenko
Journal:  Hum Gene Ther Methods       Date:  2018-03-02       Impact factor: 2.396

5.  Metalloproteases regulate T-cell proliferation and effector function via LAG-3.

Authors:  Nianyu Li; Yao Wang; Karen Forbes; Kate M Vignali; Bret S Heale; Paul Saftig; Dieter Hartmann; Roy A Black; John J Rossi; Carl P Blobel; Peter J Dempsey; Creg J Workman; Dario A A Vignali
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

6.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Authors:  Richard A Morgan; Laura A Johnson; Jeremy L Davis; Zhili Zheng; Kevin D Woolard; Elizabeth A Reap; Steven A Feldman; Nachimuthu Chinnasamy; Chien-Tsun Kuan; Hua Song; Wei Zhang; Howard A Fine; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

7.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

8.  T cell circuits that sense antigen density with an ultrasensitive threshold.

Authors:  Katelyn A Cabral; Olivia A Creasey; Rogelio A Hernandez-Lopez; Wei Yu; Maria Del Pilar Lopez Pazmino; Yurie Tonai; Arsenia De Guzman; Anna Mäkelä; Kalle Saksela; Zev J Gartner; Wendell A Lim
Journal:  Science       Date:  2021-02-25       Impact factor: 47.728

9.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.

Authors:  Kole T Roybal; Jasper Z Williams; Leonardo Morsut; Levi J Rupp; Isabel Kolinko; Joseph H Choe; Whitney J Walker; Krista A McNally; Wendell A Lim
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

Review 10.  Engineering and Design of Chimeric Antigen Receptors.

Authors:  Sonia Guedan; Hugo Calderon; Avery D Posey; Marcela V Maus
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

View more
  3 in total

1.  Designer protein circuits enable safe cancer immunotherapy.

Authors:  Mohamad Hamieh; Maria Themeli
Journal:  Nature       Date:  2022-06       Impact factor: 49.962

2.  RASA2 ablation in T cells boosts antigen sensitivity and long-term function.

Authors:  Julia Carnevale; Eric Shifrut; Nupura Kale; William A Nyberg; Franziska Blaeschke; Yan Yi Chen; Zhongmei Li; Sagar P Bapat; Morgan E Diolaiti; Patrick O'Leary; Shane Vedova; Julia Belk; Bence Daniel; Theodore L Roth; Stefanie Bachl; Alejandro Allo Anido; Brooke Prinzing; Jorge Ibañez-Vega; Shannon Lange; Dalia Haydar; Marie Luetke-Eversloh; Maelys Born-Bony; Bindu Hegde; Scott Kogan; Tobias Feuchtinger; Hideho Okada; Ansuman T Satpathy; Kevin Shannon; Stephen Gottschalk; Justin Eyquem; Giedre Krenciute; Alan Ashworth; Alexander Marson
Journal:  Nature       Date:  2022-08-24       Impact factor: 69.504

3.  SyNPL: Synthetic Notch pluripotent cell lines to monitor and manipulate cell interactions in vitro and in vivo.

Authors:  Mattias Malaguti; Rosa Portero Migueles; Jennifer Annoh; Daina Sadurska; Guillaume Blin; Sally Lowell
Journal:  Development       Date:  2022-06-23       Impact factor: 6.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.